Entera Bio Ltd. (ENTX)
2.36
-0.04 (-1.67%)
At close: Jan 14, 2025, 3:59 PM
2.34
-0.85%
After-hours Jan 14, 2025, 06:48 PM EST
undefined% (undefined)
| Bid | 2.33 |
| Market Cap | 86.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.26 |
| PE Ratio (ttm) | -9.08 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.45 |
| Volume | 13,772 |
| Avg. Volume (20D) | 129,062 |
| Open | 2.48 |
| Previous Close | 2.40 |
| Day's Range | 2.35 - 2.48 |
| 52-Week Range | 0.68 - 3.35 |
| Beta | undefined |
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2018
Employees 17
Stock Exchange NASDAQ
Ticker Symbol ENTX
Website https://www.enterabio.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 323.73% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Entera Bio Ltd. is scheduled to release its earnings on Mar 7, 2025,
during market hours.
Analysts project revenue of $40.00K, reflecting a n/a YoY growth and earnings per share of -0.08, making a 14.29% increase YoY.
Analysts project revenue of $40.00K, reflecting a n/a YoY growth and earnings per share of -0.08, making a 14.29% increase YoY.
